Clinical Reviews in Allergy & Immunology

, Volume 40, Issue 2, pp 84–91

Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis

  • Luc Mouthon
  • Alice Bérezné
  • Guillaume Bussone
  • Laure-Hélène Noël
  • Peter M. Villiger
  • Loïc Guillevin


Scleroderma renal crisis (SRC) is a major complication in patients with systemic sclerosis (SSc). It is characterized by malignant hypertension and oligo/anuric acute renal failure. SRC occurs in 5% of patients with SSc, particularly in the first years of disease evolution and in the diffuse form. The occurrence of SRC is more common in patients treated with glucocorticoids, the risk increasing with increasing dose. Left ventricular insufficiency and hypertensive encephalopathy are typical clinical features. Thrombotic microangiopathy is detected in 43% of the cases. Anti-RNA-polymerase III antibodies are present in one third of patients who develop SRC. Renal biopsy is not necessary if SRC presents with classical features. However, it can help to define prognosis and guide treatment in atypical forms. The prognosis of SRC has dramatically improved with the introduction of angiotensin-converting enzyme inhibitors (ACEi). However, 5 years survival in SSc patients who develop the full picture of SRC remains low (65%). SRC is often triggered by nephrotoxic drugs and/or intravascular volume depletion. The treatment of SRC relies on aggressive control of blood pressure with ACEi, if needed in combination with other types of antihypertensive drugs. Dialysis is frequently indicated, but can be stopped in approximately half of patients, mainly in those for whom a perfect control of blood pressure is obtained. Patients who need dialysis for more than 2 years qualify for renal transplantation.


Scleroderma renal crisis Systemic sclerosis Hypertension Acute renal failure Angiotensin-converting enzyme inhibitors 


  1. 1.
    Moore H, Sheehan H (1952) The kidney of scleroderma. Lancet 1(ii):68–70CrossRefPubMedGoogle Scholar
  2. 2.
    Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29(2):315–333CrossRefPubMedGoogle Scholar
  3. 3.
    Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD et al (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62(6):335–352Google Scholar
  4. 4.
    Steen VD, Costantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113(5):352–357PubMedGoogle Scholar
  5. 5.
    DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46(11):2983–2989CrossRefPubMedGoogle Scholar
  6. 6.
    Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M et al (2003) Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 33(5–6):216–220CrossRefPubMedGoogle Scholar
  7. 7.
    Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M et al (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67(1):110–116CrossRefPubMedGoogle Scholar
  8. 8.
    Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. Qjm 100(8):485–494CrossRefPubMedGoogle Scholar
  9. 9.
    Helfrich DJ, Banner B, Steen VD, Medsger TA (1989) Normotensive renal failure in systemic sclerosis. Arthritis Rheum 32(9):1128–1134CrossRefPubMedGoogle Scholar
  10. 10.
    Denton CP, Lapadula G, Mouthon L, Muller-Ladner U (2009) Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 48(Suppl 3):iii32–iii35CrossRefGoogle Scholar
  11. 11.
    Charles C, Clements P, Furst DE (2006) Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367(9523):1683–1691CrossRefPubMedGoogle Scholar
  12. 12.
    Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 53(1):1–46CrossRefGoogle Scholar
  13. 13.
    Rivolta R, Mascagni B, Berruti V, Quarto Di Palo F, Elli A, Scorza R et al (1996) Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum 39(6):1030–1034CrossRefPubMedGoogle Scholar
  14. 14.
    Woolfson RG, Cairns HS, Williams DJ, Hilson AJ, Neild GH (1993) Renal scintigraphy in acute scleroderma: report of three cases. J Nucl Med 34(7):1163–1165PubMedGoogle Scholar
  15. 15.
    Shapiro L, Prince R, Buckingham R (1983) D-penicillamine treatment of progressive systemic sclerosis (scleroderma). A comparison of clinical and in vitro effects. J Rheumatol 10:316PubMedGoogle Scholar
  16. 16.
    Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G, Paulus HE (1994) Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 37(1):67–74CrossRefPubMedGoogle Scholar
  17. 17.
    Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76:779–786CrossRefPubMedGoogle Scholar
  18. 18.
    Steen VD, Conte C, Day N, Ramsey-Goldman R, Medsger TA (1989) Pregnancy in women with systemic sclerosis. Arthritis Rheum 32(2):151–157CrossRefPubMedGoogle Scholar
  19. 19.
    Steen VD (1999) Pregnancy in women with systemic sclerosis. Obstet Gynecol 94(1):15–20CrossRefPubMedGoogle Scholar
  20. 20.
    Lam M, Ballou SP (1992) Reversible scleroderma renal crisis after cocaine use. N Engl J Med 326(21):1435PubMedGoogle Scholar
  21. 21.
    Denton CP, Sweny P, Abdulla A, Black CM (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33(1):90–92CrossRefPubMedGoogle Scholar
  22. 22.
    Steen VD, Medsger TA (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthr Rheum 41(9):1613–1619CrossRefGoogle Scholar
  23. 23.
    Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21(10):1838–1844PubMedGoogle Scholar
  24. 24.
    Kobayashi H, Nishimaki T, Kaise S, Suzuki T, Watanabe K, Kasukawa R (1999) Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 18(5):425–427CrossRefPubMedGoogle Scholar
  25. 25.
    Borcsok I, Schairer HU, Sommer U, Wakley GK, Schneider U, Geiger F et al (1998) Glucocorticoids regulate the expression of the human osteoblastic endothelin a receptor gene. J Exp Med 188(9):1563–1573CrossRefPubMedGoogle Scholar
  26. 26.
    Ranque B, Mouthon L (2010) Epidemiological features of systemic sclerosis. Autoimmun Rev (in press)Google Scholar
  27. 27.
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):2246–2255CrossRefPubMedGoogle Scholar
  28. 28.
    Roberts-Thomson PJ, Walker JG (2006) Scleroderma: it has been a long hard journey. Intern Med J 36(8):519–523CrossRefPubMedGoogle Scholar
  29. 29.
    Tamaki T, Mori S, Takehara K (1991) Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283(6):366–371CrossRefPubMedGoogle Scholar
  30. 30.
    Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L (2004) Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 43(9):1129–1137CrossRefGoogle Scholar
  31. 31.
    Magnant J, Diot E (2006) Systemic sclerosis: epidemiology and environmental factors. Presse Med 35(12 Pt 2):1894–1901CrossRefPubMedGoogle Scholar
  32. 32.
    Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754–763CrossRefPubMedGoogle Scholar
  33. 33.
    Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271–290PubMedGoogle Scholar
  34. 34.
    Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr, Wright TM, Metcalf JS et al (2000) Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins [letter]. J Rheumatol 27(3):821–823PubMedGoogle Scholar
  35. 35.
    Steen V (2003) Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62(2):97–99CrossRefPubMedGoogle Scholar
  36. 36.
    Manadan AM, Harris C, Block JA (2005) Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 34(4):683–688CrossRefPubMedGoogle Scholar
  37. 37.
    Molina JF, Anaya JM, Cabrera GE, Hoffman E, Espinoza LR (1995) Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 22(3):557–560PubMedGoogle Scholar
  38. 38.
    Gonzalez EA, Schmulbach E, Bastani B (1994) Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis. Am J Kidney Dis 23(2):317–319PubMedGoogle Scholar
  39. 39.
    Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D (1999) MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis 33(4):e3CrossRefPubMedGoogle Scholar
  40. 40.
    Steen VD, Syzd A, Johnson JP, Greenberg A, Jr TM (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32(4):649PubMedGoogle Scholar
  41. 41.
    Okano Y, Steen VD, Medsger TA (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119(10):1005–1013PubMedGoogle Scholar
  42. 42.
    Fisher E, Rodnan G (1958) Pathologic observations concerning the kidney in pregressive systemic sclerosis. AMA Arch Pathol 65(1):29–39PubMedGoogle Scholar
  43. 43.
    Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31(3):393–400CrossRefPubMedGoogle Scholar
  44. 44.
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B et al (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43(11):2445–2454CrossRefPubMedGoogle Scholar
  45. 45.
    Steen VD, Medsger TA (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133(8):600–603PubMedGoogle Scholar
  46. 46.
    Teixeira L, Mahr A, Berezne A, Noel LH, Guillevin L, Mouthon L (2007) Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 1108:249–258CrossRefPubMedGoogle Scholar
  47. 47.
    Caskey FJ, Thacker EJ, Johnston PA, Barnes JN (1997) Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 349(9052):620CrossRefPubMedGoogle Scholar
  48. 48.
    Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD et al (2005) Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 5(10):2565–2569CrossRefPubMedGoogle Scholar
  49. 49.
    Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Luc Mouthon
    • 1
    • 4
  • Alice Bérezné
    • 1
  • Guillaume Bussone
    • 1
  • Laure-Hélène Noël
    • 2
  • Peter M. Villiger
    • 3
  • Loïc Guillevin
    • 1
  1. 1.UPRES EA 4058, Pôle de Médecine Interne, Centre de Référence pour les vascularites nécrosantes et la sclérodermie systémique, hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP)Université Paris DescartesParisFrance
  2. 2.Necker hospital, INSERM U507Paris-Descartes UniversityParisFrance
  3. 3.Department of Rheumatology, Clinical Immunology and AllergologyUniversity Hospital and University of BernBernSwitzerland
  4. 4.Department of Internal MedicineCochin HospitalParis Cedex 14France

Personalised recommendations